100 assets in Marginal Zone Lymphoma

Therapeutic assets addressing Marginal Zone Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Iopofosine (¹³¹I) Marginal Zone Lymphoma	Cellectar Biosciences, Inc.	P2	CCC (51)
Baff-R Car-T Marginal Zone Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P1/2	CCC (48)
Zandelisib Marginal Zone Lymphoma	MEI Pharma, Inc.	P3	CCC (48)
Pemigatinib Marginal Zone Lymphoma	University of Utah	P2	CC (47)
Selinexor Marginal Zone Lymphoma	Barbara Ann Karmanos Cancer Institute	P1/2	CC (47)
Autologous Baffr-Targeting Car T Cells Marginal Zone Lymphoma	Mayo Clinic	P1	CC (43)
Autologous Cd19Car-Cd28-Cd3Zeta-Egfrt-Expressing Tcm-Enriched T Cells Marginal Zone Lymphoma	City of Hope Medical Center	P1	CC (43)
Autologous Cd19Car-Cd28-Cd3Zeta-Egfrt-Expressing Tn/Mem-Enriched T-Lymphocytes Marginal Zone Lymphoma	City of Hope Medical Center	P1	CC (43)
Bgb-16673 Marginal Zone Lymphoma	BeiGene	P1/2	CC (43)
Bgb-21447 Marginal Zone Lymphoma	BeOne Medicines	P1	CC (43)
Btk-In-24 Marginal Zone Lymphoma	Nurix Therapeutics, Inc.	P1	CC (43)
ctx112 Marginal Zone Lymphoma	CRISPR Therapeutics AG	P1/2	CC (43)
eo2463 Marginal Zone Lymphoma	Enterome	P1/2	CC (43)
exs73565 Marginal Zone Lymphoma	Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.	P1	CC (43)
Hmpl-760 Marginal Zone Lymphoma	Hutchmed	P1	CC (43)
Loxo-338 Marginal Zone Lymphoma	Eli Lilly and Company	P1	CC (43)
Ltz-301 Marginal Zone Lymphoma	LTZ Therapeutics, Inc.	P1	CC (43)
ly4152199 - iv Marginal Zone Lymphoma	Eli Lilly and Company	P1	CC (43)
Pevonedistat Marginal Zone Lymphoma	City of Hope Medical Center	P1	CC (43)
Vnx-101 Marginal Zone Lymphoma	Vironexis Biotherapeutics Inc.	P1/2	CC (43)
Zelebrudomide Marginal Zone Lymphoma	Nurix Therapeutics, Inc.	P1	CC (43)
ace1831 Marginal Zone Lymphoma	Acepodia Biotech, Inc.	P1	CC (42)
Diphenhydramine Marginal Zone Lymphoma	National Cancer Institute (NCI)	P1	CC (42)
Prednisolone Marginal Zone Lymphoma	National Cancer Institute (NCI)	P1	CC (42)
prt2527 Marginal Zone Lymphoma	Prelude Therapeutics	P1	CC (42)
Adi-001 Marginal Zone Lymphoma	Adicet Therapeutics	P1	C (39)
BP1002 Marginal Zone Lymphoma	Bio-Path Holdings, Inc.	P1	C (39)
cd19.20.22 car t cells Marginal Zone Lymphoma	University of Maryland, Baltimore	P1	C (39)
cd22 car-t Marginal Zone Lymphoma	Stanford University	P1	C (39)
cd79b-19 car t cells Marginal Zone Lymphoma	Marcela V. Maus, M.D.,Ph.D.	P1	C (39)
Docirbrutinib Marginal Zone Lymphoma	Carna Biosciences, Inc.	P1	C (39)
lp-168 Marginal Zone Lymphoma	Newave Pharmaceutical Inc	P1	C (39)
lv20.19 car t cells Marginal Zone Lymphoma	Medical College of Wisconsin	P1	C (39)
PRT1419 Marginal Zone Lymphoma	Prelude Therapeutics	P1	C (39)
psb202 Marginal Zone Lymphoma	Qilu Puget Sound Biotherapeutics (dba Sound Biologics)	P1	C (39)
Synkir-310 Marginal Zone Lymphoma	Verismo Therapeutics	P1	C (39)
Allogeneic Natural Killer Cells Marginal Zone Lymphoma	Paolo Caimi, MD	P1	C (37)
ft596 Marginal Zone Lymphoma	Fate Therapeutics	P1	C (37)
64Cu-LLP2A Marginal Zone Lymphoma	Washington University School of Medicine	Early P1	C (36)
Magrolimab Marginal Zone Lymphoma	National Cancer Institute (NCI)	P1	C (32)
ms-553 Marginal Zone Lymphoma	MingSight Pharmaceuticals, Inc	P1/2	D (30)
Mtm-H-001 Marginal Zone Lymphoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	N/A	D (30)
Anti-Cd20/Cd3 Monoclonal Antibody Regn1979 Marginal Zone Lymphoma	Regeneron Pharmaceuticals	P3	NR ()
Apg-3288 Marginal Zone Lymphoma	Ascentage Pharma Group Inc.	P1	NR ()
CD47/SIRPA-BLOCKING AGENT ALX148 Marginal Zone Lymphoma	M.D. Anderson Cancer Center	P1/2	NR ()
Jwcar239 Marginal Zone Lymphoma	Peking University Cancer Hospital & Institute	P1	NR ()

Showing 51 to 100 of 100 assets

PreviousPage 2 of 2Next